What the FDA record means now
Can a pharmacy make BPC-157 today?
FDA's 503A rule covers medicine made for one named patient. BPC-157 entered Category 2 in 2023, then its requests were withdrawn; FDA hasn't said what pharmacies may do now.
Why might BPC-157's pharmacy status change?
An FDA advisory panel discussed BPC-157 in July 2026, so the BPC-157 pharmacy status could still change. BPC-157 was on the agenda for that panel meeting on July 23-24, 2026 [18].
The panel took up whether to add the compound to the 503A list, and FDA staff had advised against adding it. That list names raw ingredients some pharmacies may use for one patient's prescription.
The agenda also names TB-500, a different lab-made compound. That other compound does not help you answer the pharmacy question here.
A panel meeting doesn't approve a drug or change today's rules. The panel talks first, and FDA must take a separate legal step later.
Rules could still change, but the meeting isn't permission to make or use the compound. As of September 2026, FDA had posted no record of the panel's votes. FDA must act before the rule changes.
These are broad legal and health facts. A doctor or lawyer must answer questions about your own case, and this site sells or supplies nothing.
What does FDA say today?
FDA first listed "BPC-157 (free base)" and "BPC-157 acetate" in Category 2; those words name two chemical forms, not two approved medicines. Its April 22, 2026 page says both requests were withdrawn, yet the safety concerns remain [16].
That listing began with the September 29, 2023 update for ingredients under 503A [16]. FDA worried about immune reactions, unwanted material from making the compound, and whether the label named the right active ingredient.
Because the requests were withdrawn, FDA no longer puts BPC-157 in Category 2. FDA hasn't said what the change lets a 503A one-patient pharmacy do.
BPC-157 is also not an FDA-approved drug [16]. A raw ingredient may be considered for pharmacy use without making BPC-157 an approved finished medicine.
Some early 2026 reports said the compound was heading to Category 1. No page on FDA.gov says it moved from Category 2 on a set date.
FDA clearly placed BPC-157 in Category 2, then marked the requests withdrawn. Because FDA hasn't explained the result, a pharmacy can't treat withdrawal as permission.
How do 503A and 503B pharmacies differ?
Federal law separates two kinds of pharmacy-made drugs. The 503A rule covers medicine made for one named patient by a licensed pharmacy or doctor.
The 503B rule covers a special facility that makes larger batches for clinics to keep on hand. Unlike an ordinary pharmacy, that facility registers with FDA and faces agency checks [17].
A pharmacy may not choose just any raw ingredient. The ingredient must meet a recognized drug-quality book, have prior use in a drug FDA approved, or be on FDA's list [17].
An ingredient not on the list goes through a public request and review. A pharmacy panel advises FDA, but the agency makes the final choice.
FDA once called pending items Category 1 or Category 2. Since January 7, 2025, new requests no longer enter those numbered groups [17].
For an old Category 1 item, FDA may wait before taking action while it reviews the request. FDA would not wait for a Category 2 item because the agency had found a major safety concern.
BPC-157 left Category 2 when the requests were withdrawn [16]. FDA still shows the concerns and hasn't said whether a 503A pharmacy may now make it.
What answer can a pharmacy give you now?
FDA hasn't said whether a 503A pharmacy, which makes medicine for one named patient, may make BPC-157 after the requests were withdrawn. A pharmacy can't treat withdrawal alone as clear permission.
If an ingredient is allowed and the care fits you, a prescriber writes a prescription in your name. A 503A pharmacy makes that one-patient order; a 503B facility makes larger batches for clinics [17].
A phone or video visit cannot add an ingredient to the permitted list. You still need a proper health visit and a valid prescription [17].
A raw ingredient must still qualify under federal pharmacy rules. A Category 2 ingredient carried a major safety concern, so routine 503A use wasn't allowed [16].
The safety limit came from the old listing. After the requests were withdrawn, FDA gave pharmacies no clear new instruction.
Another review took place in July 2026 [18]. That meeting hasn't changed the rule, and its outcome is not on FDA's public record.
These are broad facts, not an answer for your own health or legal case. This page neither sells nor supplies BPC-157 or any other substance.